Antidepressants: Types, Mechanisms, and Clinical Uses

Antidepressants are among the most prescribed medications in the United States — the Centers for Disease Control and Prevention estimates that roughly 13% of Americans aged 18 and older reported taking antidepressant medication in a given 30-day period, based on data from the National Health and Nutrition Examination Survey. These drugs span multiple chemical classes, each with a distinct mechanism of action and clinical profile. Understanding those differences matters not just for clinicians but for anyone trying to make sense of a prescription, a treatment change, or a conversation with a psychiatrist.

Definition and scope

An antidepressant is a psychiatric medication prescribed primarily to treat depression and mood disorders, though the term has long outgrown its name. The same drugs are now first-line or adjunct treatments for anxiety disorders, obsessive-compulsive disorder, PTSD and trauma-related disorders, eating disorders, chronic pain syndromes, and premenstrual dysphoric disorder — a scope that catches many people off guard when they first see the prescription.

The broad category of antidepressants includes five major classes:

1. Selective Serotonin Reuptake Inhibitors (SSRIs) — fluoxetine, sertraline, escitalopram, paroxetine, citalopram, fluvoxamine
2. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) — venlafaxine, duloxetine, desvenlafaxine, levomilnacipran
3. Tricyclic Antidepressants (TCAs) — amitriptyline, nortriptyline, imipramine, clomipramine
4. Monoamine Oxidase Inhibitors (MAOIs) — phenelzine, tranylcypromine, selegiline (transdermal)
5. Atypical antidepressants — bupropion, mirtazapine, trazodone, vilazodone, vortioxetine

Each class carries a distinct risk-benefit profile, and clinicians weigh symptom pattern, comorbidities, prior medication history, and potential drug interactions before selecting one. This is not a one-size-fits-all pharmacopeia.

How it works

The dominant theory linking these drugs to their effects centers on monoamine neurotransmitters — primarily serotonin, norepinephrine, and dopamine — though researchers at institutions including the National Institute of Mental Health acknowledge that the full picture is more complex than simple neurotransmitter deficiency.

SSRIs block the reuptake transporter that pulls serotonin back into the presynaptic neuron after it is released. More serotonin remains available in the synaptic cleft, and over time — typically 2 to 6 weeks — downstream receptor adaptations appear to produce antidepressant effect. The delayed onset is one of the more clinically important features: the drug is doing something from day one, but patients rarely feel it that quickly.

SNRIs inhibit reuptake of both serotonin and norepinephrine. The added norepinephrine component is why SNRIs like duloxetine have established efficacy in pain conditions — fibromyalgia, diabetic peripheral neuropathy — as well as in major depression and generalized anxiety.

TCAs also block serotonin and norepinephrine reuptake, but with considerably less selectivity. They antagonize histamine, acetylcholine, and alpha-adrenergic receptors, producing sedation, dry mouth, constipation, orthostatic hypotension, and significant cardiac conduction effects. In overdose, TCAs carry a narrow therapeutic index — a practical reason they are rarely first-line today.

MAOIs work by inhibiting the monoamine oxidase enzyme responsible for breaking down serotonin, norepinephrine, and dopamine in the synapse. They are highly effective — particularly for atypical depression — but require dietary restriction of tyramine-containing foods (aged cheeses, cured meats, certain wines) to avoid hypertensive crisis. Drug interactions with MAOIs can be severe, including life-threatening serotonin syndrome when combined with other serotonergic agents.

Atypical agents are a genuinely miscellaneous group. Bupropion inhibits reuptake of dopamine and norepinephrine with negligible serotonin activity, which makes it distinctly useful when serotonergic side effects — sexual dysfunction, emotional blunting — are a concern. Mirtazapine blocks alpha-2 autoreceptors and certain serotonin receptors, increasing noradrenergic and serotonergic transmission through a different upstream mechanism; its antihistamine properties make it sedating and appetite-stimulating, which can be therapeutically valuable in patients with insomnia and low weight.

Common scenarios

Antidepressants appear across a wide range of clinical presentations in medication for mental health practice:

• Major depressive disorder (MDD): SSRIs are typically first-line per American Psychiatric Association practice guidelines. Sertraline and escitalopram consistently rank among the best-tolerated options in head-to-head meta-analyses, including the 2009 Cipriani et al. analysis published in The Lancet.
• Generalized anxiety disorder: SSRIs and SNRIs carry FDA approval for GAD; response is comparable to their antidepressant efficacy.
• Panic disorder and social anxiety: SSRIs and venlafaxine are established first-line agents.
• OCD: Clomipramine (a TCA) and SSRIs — particularly at higher doses than those used for depression — remain standard. Fluvoxamine, fluoxetine, sertraline, and paroxetine each carry FDA approval for OCD.
• PTSD: Sertraline and paroxetine are the only FDA-approved pharmacotherapies for PTSD specifically, though other SSRIs are widely used in practice.
• Chronic pain and somatic syndromes: Duloxetine has FDA approval for diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain — uses that have nothing to do with depression per se.

Decision boundaries

Choosing among antidepressant classes involves more than matching a drug to a diagnosis. Comorbidities shift the calculus considerably. A patient with bipolar disorder requires particular caution — antidepressant monotherapy in bipolar depression can precipitate manic episodes, and mood stabilizer coverage is generally prioritized first.

Tolerability often determines adherence, which determines outcomes. Sexual dysfunction affects an estimated 30% to 40% of patients on SSRIs or SNRIs, according to data compiled by the Mayo Clinic — a side effect that frequently goes undisclosed unless clinicians ask directly. Bupropion is associated with significantly lower rates of sexual dysfunction, and that difference is clinically decisive for a meaningful subset of patients.

Stopping antidepressants abruptly — particularly paroxetine and venlafaxine, which have short half-lives — can produce discontinuation syndrome: dizziness, flu-like symptoms, sensory disturbances sometimes described as "brain zaps." This is not addiction, but it does argue strongly for tapering under clinical guidance rather than stopping cold.

For patients whose depression does not respond to an initial antidepressant, the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial — the largest antidepressant effectiveness study ever conducted by the National Institute of Mental Health, involving over 4,000 participants — found that roughly one-third of patients achieved remission with the first medication tried, and that subsequent strategies including switching agents, combining medications, or adding psychotherapy approaches increased cumulative remission rates incrementally across treatment steps. The trial's data remain the most cited real-world benchmark for treatment-resistant depression expectations in US clinical practice.